The European Medicines Agency (EMA) announced on Wednesday 17 November that it had received a conditional marketing authorisation application for the Covid-19 vaccine Nuvaxovid (NVX-CoV2373) developed by the US laboratory Novavax.
The Agency has already examined a large amount of data on this vaccine, the rolling review of which started in February 2021.
As a result, the review of the application for authorisation “will proceed under an accelerated timeline, and an opinion on the...